SciELO - Scientific Electronic Library Online

 
vol.37 número4Enfermedad renal crónica en individuos hipertensos ≥60 años atendidos en Atención PrimariaUna nueva mutación fundadora en SLC12A3 (p.Val647Met) en pacientes con síndrome de Gitelman de etnia gitana índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Nefrología (Madrid)

versão On-line ISSN 1989-2284versão impressa ISSN 0211-6995

Resumo

MONFA, Elena et al. Intermediate steroid withdrawal after renal transplantation and anti-HLA antibodies (HLA-Abs) development. Nefrología (Madr.) [online]. 2017, vol.37, n.4, pp.415-422. ISSN 1989-2284.  https://dx.doi.org/10.1016/j.nefro.2017.02.002.

Introduction:

Steroid withdrawal in renal transplantation is desirable to avoid their adverse effects. However, by decreasing the immunosuppression, could lead to an increased risk for the development of HLA-Abs.

Objective:

Evaluate the relationship between steroid withdrawal and development of HLA-Abs in renal transplantation.

Methods:

We analyzed sera by Luminex from 182 kidney transplants performed from 1998 to 2011, before and two years after transplantation. All the patients had a pretransplant PRA (panel reactive of antibodies) <20% by complement-dependent cytotoxicity (CDC) and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF). We compared a group of steroid withdrawal at 7 months (group-I; n = 130) and another control with non-withdrawal (group-II; n = 52).

Results:

22 patients (16.9%) in group-I and 11 patients in group-II (21.1%) had HLA-Abs after two years (pNS). Despite excluding patients with PRA >20%, we detected HLA-Abs pretransplant by Luminex in 11.5% of patients in both groups, of which, 66.6%, versus 53% (p 0.058), developed new specificities, with a similar percentage of donor specific antibodies (DSA) in both groups (33.33% vs 36.36%), pNS. In the subgroup without pretransplant HLA-Abs (group-I; n = 115, group-II; n = 45), 6.08% developed de novo HLA-Abs, being DSA 3.4% (Group-I) versus 7.69% in group II with 3.84% DSA (pNS).

Conclusions:

Steroid withdrawal at 7 months of renal transplantation does not entail a higher risk in terms of HLA-Abs development in patients without pretransplant HLA-Abs and treatment with tacrolimus and MMF, although larger studies are needed to confirm these findings.

Palavras-chave : Kidney transplantation; Immunosuppression; Withdrawal; Steroids; Anti-HLA-antibodies.

        · resumo em Espanhol     · texto em Inglês     · Inglês ( pdf )